Loading

Innate Antiviral Immunity as a Double-Edged Determinant of Oncolytic Virotherapy Outcomes
Oncolytic virotherapy (OVT) has emerged as a promising cancer immunotherapy strategy that combines selective tumor cell infection and lysis with immune activation. However, clinical responses remain variable, and innate antiviral immunity is a key determinant of this variability. Type I interferon (IFN) signaling and downstream interferon-stimulated genes can restrict viral replication, limit intratumoral spread, and reduce direct oncolysis, particularly in tumors with intact or elevated antiviral programs.
Mechanistic Drivers, Translational Gaps, and Modeling Approaches for Ocular Adverse Events in Antibody–Drug Conjugate Therapy
Antibody–drug conjugates (ADCs), which merge the specificity of monoclonal antibodies with potent cytotoxic payloads, are becoming more common as a therapeutic option for cancer patients with multiple approvals and many more in clinical development. As of March 2026, 15 ADCs have been approved by the FDA for use in oncological indications (Table 1), and despite their targeted design, ocular adverse events (OAEs) have emerged as adverse events of special interest in patients across various tumor types.
Bridging the Global Gap: The Potential of Nutraceuticals in Addressing Cervical Cancer Disparities
Human Papilloma Virus (HPV)-related cervical cancer (CC) still drives cancer-related mortality in low-to-middle income countries (LMICs), exacerbated by disparities in HPV screening, HPV vaccination status, specialist availability, and treatment costs compared to higher-income countries. This study describes how botanical nutraceuticals may provide a viable, low-cost strategy to target molecular hallmarks of HPV-related CC that would specifically benefit regions with limited access to specialized oncologists or radiotherapy infrastructure.
Cancer of Unknown Primary Site in the Era of Molecular Diagnosis, Staging and Precision Therapy: A Commentary
The clinicopathological syndrome of cancer of unknown primary site (CUP) is metastatic cancer without an identifiable anatomical primary site after a thorough evaluation and has been a diagnostic and therapeutic puzzle for many decades frustrating physicians and patients. Postmortem examinations have found very small clinically undetectable primary tumors in about 75% of cases from more than 20 different sites; even at autopsy very small primaries which are not visible or palpable are difficult to find and would require hundreds of blind tissue sections from every organ to detect.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.